Ferrostatin-1 (Fer-1),347174-05-4,IC-0215645

Ferrostatin-1 is a potent inhibitor of ferroptosis with an EC50 of 60 nM.
Ferrostatin-1, as an molecular inhibitor, can block ferroptosis. Ferrostatins are believed to act by preventing oxidative damage to membrane lipids. Ferrostatin-1, an arylalkylamine with antioxidative properties, was identified as one of the first inhibitors of ferroptosis. Ferrostatin-1 attenuates oxidative, iron-dependent cell death in cancer cells treated with small molecules such as erastin. [3]
Ferrostatin-1, an inhibitor of ferroptosis, has an EC50 of 60 nM (HT-1080). Besides, Ferrostatin-1 was able to inhibit a non-apoptotic cell death named ferroptosis. The neuroprotective role of Ferrostatin-1 under rotenone-induced oxidative stress in dopaminergic neuroblastoma cells (SH-SY5Y) was reported. Ferrostatin-1 inhibited the ROS/RNS generated under rotenone insult in SH-SY5Y cells. The effective role of Ferrostatin-1 in ER stress mediated activation of apoptotic pathway was confirmed. Additionally, Ferrostatin-1 mitigated rotenone-induced α-syn aggregation was also reported.[1]
Ferrostatin-1, a specific inhibitor of ferroptosis, was Administrated to prevent neuronal death and reduced iron deposition induced by hemoglobin in organotypic hippocampal slice cultures (OHSCs). Mice treated with ferrostatin-1 after ICH exhibited marked brain protection and improved neurologic function. Additionally, Ferrostatin-1 reduced lipid reactive oxygen species production and attenuated the increased expression level of PTGS2 and its gene product cyclooxygenase-2 ex vivo and in vivo. For in vivo experiments, Ferrostatin-1 was injected 1 pmol (10 μM Ferrostatin-1 in 1 μl 0.01% DMSO in saline) into the striatum immediately after collagenase injection or into the cerebral ventricle 2 hours after collagenase injection. The coordinates for cerebral ventricle injection were: 1.0 mm lateral, 0.5 mm posterior, and 2.5 mm in depth relative to the bregma. [2]